1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Carbonic Anhydrase
  4. CA I Isoform
  5. CA I Inhibitor

CA I Inhibitor

CA I Inhibitors (20):

Cat. No. Product Name Effect Purity
  • HY-149301
    hCAIX-IN-18
    Inhibitor 98.52%
    hCAIX-IN-18 (compound 30) is an inhibitor of carbonic anhydrase (CA), with Kis of 3.5 nM, 9.4 nM, 43.0 nM and 8.2 nM for hCAI, hCAII, hCAIX, hCAXII, respectively. hCAIX-IN-18 can be used for cancer research.
  • HY-161322
    hCAXII-IN-9
    Inhibitor
    hCAXII-IN-9 (Compound 3I) is a selective inhibitor of hCAXII with Ki values of 28 nM, 7192.6 nM, 188.6 nM, and >100000 nM for hCAXII, hCAI, hCAII, and hCAIX, respectively. hCAXII-IN-9 can be utilized in antitumor research.
  • HY-150570
    Carbonic anhydrase inhibitor 14
    Inhibitor
    Carbonic anhydrase inhibitor 14 (Compound 8b) is a carbonic anhydrase (CA) inhibitor with Ki values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 14 can also inhibit CDK2 with an IC50 of 20.3 μM. Carbonic anhydrase inhibitor 14 shows antitumor activity.
  • HY-161142
    Carbonic anhydrase/AChE-IN-1
    Inhibitor
    Carbonic anhydrase/AChE-IN-1 (compound 16) is a carbonic anhydrase and AChE inhibitor with Kis of 24.42 nM, 19.95 nM, and 5.07 nM for hCA I, hCA II, and AChE, respectively.
  • HY-158372
    hCA I-IN-3
    Inhibitor
    hCA I-IN-3 (compound 24), an aryl ether derivative, is a potent carbonic anhydrase inhibitor. hCA I-IN-3 can inhibit carbonic anhydrase hCA I and hCA II isoenzymes, with IC50 values of 4.77 and 9.66 nM, respectively. hCA I-IN-3 can be used for cancer research.
  • HY-149269
    COX-2-IN-30
    Inhibitor
    COX-2-IN-30 is a benzenesulfonamide derivative, as well as an orally active and dual inhibitor of COX (IC50=49 nM for COX-2, 10.4 μM for COX-1) and 5-LOX (IC50=2.4 μM). COX-2-IN-30 also inhibits transmembrane hCA IX and hCA XII isoform with nanomolar calss Ki values. COX-2-IN-30 exhibits analgesic, anti-inflammatory, and ulcerogenic activities, and does not show acute gastric effect.
  • HY-146207
    HCAIX-IN-2
    Inhibitor
    HCAIX-IN-2 (compound 9d) is a selective carbonic anhydrase inhibitor with the Ki values of 24.6 nM and 45.3 nM for hCA IX and hCA XII, respectively.
  • HY-151578
    DPP IV/hCA II-IN-1
    Inhibitor
    DPP IV/hCA II-IN-1 is a potent and selective dipeptidyl peptidase IV (DPP IV) and carbonic anhydrase (CA) inhibitor with an IC50 value of 0.049 μM for DPP IV and with Ki values of 0.0361, 0.0428, 0.0941, 0.1328, 0.2615, and 3.034 μM for CA II, CA VB, CA VA, CA IX, CA I, and CA IV, respectively.
  • HY-161282
    hCAII-IN-10
    Inhibitor
    hCAII-IN-10 (compound 11d) is hCA II inhibitor with the IC50s of 14 nM and 29.2 μM for hCA II and hCA I, respectively. hCAII-IN-10 inhibits cell growth against HT-29 cells with the IC50 of 74 μM. hCAII-IN-10 shows strongly lowered intraocular pressure in the glaucomatous rabbit eye model.
  • HY-156181
    hCAIX/XII-IN-8
    Inhibitor
    hCAIX/XII-IN-8 (compound 3g) is a potent human (carbonic anhydrase) CA IX and XII inhibitor, with Ki values of 8.5 and 6.7 nM, respectively. hCAIX/XII-IN-8 shows particularly strong inhibitory activity against the tumor-associated membrane-bound isoforms, hCA IX and XII, while maintaining a high selectivity ratio over cytosolic off-target isoforms hCA I and II.
  • HY-159128
    hCAIX-IN-21
    Inhibitor
    hCAIX-IN-21 (compound 16c) is a potent hCAIX inhibitor with KI values of 5.2, 3.5, 12.6, 13600 nM for hCAIX, hCA II, hCA XII, hCA I, respectively. hCAIX-IN-21 inhibits cathepsin B enzyme activity.
  • HY-161507
    hCAI/II-IN-8
    Inhibitor
    hCAI/II-IN-8 (Compound 8) is a hydrazide derivative based on 4-hydroxybenzaldehyde. hCAI/II-IN-8 primarily targets human carbonic anhydrase isomerase I (hCA I) and II (hCA II) for inhibition (IC50 = 21.35 ± 0.39 nM (hCA I); 7.12 ± 0.12 nM (hCA II)). hCAI/II-IN-8 inhibits AChE and BChE as well(IC50 = 46.27 ±0.75 nM (AChE); 43.38 ± 0.83 nM (BChE)). ..
  • HY-163380
    CA/MAO-B-IN-1
    Inhibitor 98.34%
    CA/MAO-B-IN-1 (Compound 78) is a dual inhibitor for human brain carbonic anhydrases (CA) and Monoamine Oxidase-B (MAO-B), with IC50s of 8.8 and 7.0 nM, respectively. CA/MAO-B-IN-1 reveals a human oral absorption of 71.9% through in silico prediction.
  • HY-162063
    hCAIX/XII-IN-9
    Inhibitor
    hCAIX/XII-IN-9 (compound 8) is a potent carbonic anhydrase (CA) inhibitor with Ki values of 1658 nM, 184.8 nM, 8.9 nM, 64.8 nM for hCA I, hCA II, hCA IX, and hCA XII, respectively.
  • HY-162226
    Carbonic anhydrase inhibitor 19
    Inhibitor
    Carbonic anhydrase inhibitor 19 (compound 26a) inhibits the Glaucoma related isoforms hCA II and hCA XII with Kis of 9.4 nM and 6.7 nM, respectively. Carbonic anhydrase inhibitor 19 reveals an intraocular pressure (IOP) lowering effect.
  • HY-146206
    HCAIX-IN-1
    Inhibitor
    HCAIX-IN-1 (compound 21e) is a potent and selective HCAIX inhibitor with KIs of 694.9, 126.6, 3.3, 9.8 nM for hCA I, hCA II, hCA IX, hCA XII, respectively.
  • HY-161374
    Carbonic anhydrase inhibitor 20
    Inhibitor
    Carbonic anhydrase inhibitor 20 (compound 11) is an inhibitor of piperazinosulfonamide carbonic anhydrase (Carbonic Anhydrase). The Ki of Carbonic anhydrase inhibitor 20 for hCA I, hCA II, hCA IX, and hCA XII are 47.6 nM, 36.5 nM, 8.3 nM, and 2.7 nM respectively.
  • HY-156169
    hCAIX/XII-IN-7
    Inhibitor
    hCAIX/XII-IN-7 (compound 3e) is a potent hCA IX and XII inhibitor with Kis of 3.2 nM, 9.2 nM, 503.7 nM and 59 nM for hCA I, hCA II, hCA IX and hCA XII, respectively. hCAIX/XII-IN-7 has the potential for hypoxic tumors research.
  • HY-163753
    Carbonic anhydrase inhibitor 25
    Inhibitor
    Carbonic anhydrase inhibitor 25 (compound 6a) is a potent carbonic anhydrase inhibitor. Carbonic anhydrase inhibitor 25 shows inhibition for hCA I and hCA II receptor.
  • HY-157321
    hCAI/II-IN-7
    Inhibitor
    hCAI/II-IN-7 (compound 1F) is a potent carbonic anhydrase (CA) inhibitor with Ki values of 23 nM, 44 nM and 20.57 µM for hCA-I, hCA-II and bovine CA, respectively.